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Introduction. Glioblastoma (GBM) is the most common primary adult brain tumour with a median overall survival (OS) of 12–15
months. Molecular characterization of multiple immunooncology targets in GBM may help target novel immunotherapeutic
strategies. We used NanoString GeoMx® Digital Spatial Profiling (DSP) to assess multiple immunooncology protein targets inmethylated versus unmethylated IDH-wild-type glioblastoma.Methods. NanoString GeoMx® DSP technology uses multiple primaryantibodies conjugated to indexing DNA oligos with a UV photocleavable linker. Tissue regions of interest (ROIs) are selected with
bound fluorescent antibodies; oligos are released via a UV-mediated linker and quantitated. We used DSP multiplex analysis of 31
immunooncology proteins and controls (CD4, CD14, CD68, CD8A, B7-H3, PD-L1, CD19, FOXP3, CD44, STAT3 (phospho Y705),
CD45, Pan Cytokeratin, MS4A1/CD20, CD45RO, PD1, CD3, beta-2 microglobulin, VISTA, Bcl2, GZMB, PTEN, beta-catenin, CD56,
Ki-67, STAT3, AKT, p-Akt, S6, Histone H3, IgG Rabbit control, and Mouse IgG control) from ROIs in a cohort of 10 IDH-wild-type
glioblastomas (5 methylated and 5 unmethylated). An nCounter platform allowed quantitative comparisons of antibodies between
ROIs inMGMTmethylated and unmethylated tumours.Mean protein expression counts betweenmethylated and unmethylated GBM
were compared using technical and biological replicates. Results. +e analysis showed 10/27 immunooncology target proteins were
significantly increased in methylated versus unmethylated IDH-wild-type glioblastoma tumour core (false discovery rate (FDR) <0.1
by Benjamini–Hochberg procedure). Conclusions. NanoString GeoMx® DSP was used to analyse multiple immunooncology proteintarget expression inmethylated versus unmethylated IDH-wild-type glioblastoma. In this small study, there was a statistical increase in
CD4, CD14, CD68, CD8A, B7-H3, PDL-1, CD19, FOXP3, CD44, and STAT3 protein expression in methylated versus unmethylated
GBM tumour core; however, this requires larger cohort validation. Advanced multiplex immunooncological biomarker analysis may
be useful in identifying biomarkers for novel immunotherapeutic agents in GBMs.
1. Introduction
Glioblastoma (GBM), the most common primary malig-
nancy in adults, has an annual incidence of 3.2 per 100,000
[1]. Despite advances in surgical resection, chemotherapy,
and radiotherapy, GBM has a very poor prognosis [2].
Immune checkpoint inhibitors (ICIs) have shown efficacy in
several cancers, including, and in particular, melanoma,
head and neck cancer, renal cell carcinoma, non-small-cell
lung cancer, and colorectal cancer [3–7]. ICIs, such as
nivolumab and pembrolizumab, act to increase the immune
response to an individual tumour by blocking the PD-1/PD-
L1 interaction between host and tumour which may in part
inhibit a T-cell-mediated immune reaction and allow the
tumour to evade the normal protective immune response
[8]. Several clinical trials are underway to investigate the use
of ICIs to enhance the immune response in GBM [9]. In
particular, CheckMate 143, a randomized phase 3 clinical
trial evaluating the efficacy and safety of PD-1 inhibitor
nivolumab Opdivo in patients with first recurrence of
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glioblastoma multiforme (GBM), did not meet its primary
endpoint of improved overall survival over bevacizumab
monotherapy highlighting the need for more detailed
analysis of immunooncology biomarkers within GBM in
order to better target novel immune therapeutics [10, 11].
Previous work in a cohort of 135 GBMs detected PD-L1 gene
expression and Tumour Infiltrating Lymphocytes (TILs) in
the majority of GBM cases suggesting potential utility of
ICIs, although PD-L1 expression and TILs density were
shown to be unrelated to GBM outcome and methylation
status was not well defined [12].
Protein expression in formalin-fixed, paraffin-embedded
(FFPE) tissue is conventionally measured by immunohis-
tochemistry or immunofluorescence on a small number of
proteins. By contrast, novel NanoString Digital Spatial
Profiling (DSP) technology allows highly multiplexed and
spatially resolved analysis of protein or RNA targets in
multiple of Regions of Interest (ROIs) in FFPE tissue. With
the theoretical ability to determine up to 800 protein targets
on one FFPE section down to single-cell resolution, multiple
analytes, including immune targets, can be measured si-
multaneously using an optical-barcode-based platform [13].
Furthermore, this technology enables multiple ROIs to be
analysed, increasing the likelihood of identifying and lo-
cating variations in targets across the tissue due to intra-
tumour heterogeneity [14].
We used NanoString GeoMx® Digital Spatial Profiling(DSP) technology in 10 cases of IDH-wild-type glioblastoma
[15] to quantify 27 immunooncology protein targets be-
tween ROIs in MGMT methylated and unmethylated tu-
mours, additionally comparing tumour core and invasive
margin regions.
2. Materials and Methods
DSP (see Figure 1) was undertaken using a cocktail of
primary antibodies (NanoString GeoMx® Digital SpatialProfiling [DSP] technology immune panel Table 1) each with
a unique, UV photocleavable indexing oligo. +e tissue slide
was placed on the stage of an inverted microscope. A custom
gasket was then clamped onto the slide, allowing the tissue to
be submerged in 1.5mL of buffer solution. +e micro-
capillary tip was connected to a syringe pump primed with
buffer solution, allowing for accurate aspiration of small
volumes (<10 µL). Under the microscope, wide-field fluo-
rescence imaging was performed with epi-illumination from
a visible LED light engine. +e ROI was then located using
fluorescence imaging. A 20x image corresponded to
650 µm× 650 µm of tissue area using a Complementary
Metal Oxide Semiconductor (CMOS) camera. +e com-
posite 20x images provided a high-resolution image of the
ROI. +e ROIs were then selected based on the fluorescence
information and sequentially processed by the microscope
automation.
+e steps performed for each ROI by the microscope
automation were as follows. First, the microcapillary tip was
washed by dispensing clean buffer out of the capillary and
into a wash station. Next, the tissue slide was bulk washed by
exchanging the buffer solution on the slide via the inlet and
outlet wash ports on the gasket clamp.+emicrocapillary tip
was then moved into position directly over the ROI with
50 µm from the tissue. +e local region of tissue around the
ROI was washed by dispensing 100 µL of buffer solution
from the microcapillary. +en, the area of tissue within the
ROI was selectively illuminated with UV light to release the
indexing oligos. UV LED light was collimated to be reflected
from the Digital Mirror Device (DMD) surface into the
microscope objective and focused at the sample tissue. Each
micro mirror unit in the DMD corresponded to ∼1 µm2 area
of sample and reflects the UV light in a controlled pattern
based on the ROI selection in the image. Following each UV
illumination cycle, the eluent was collected from the local
region via microcapillary aspiration and transferred to an
individual well of a microtiter plate/strip tube. Once all ROIs
were processed, indexing oligos were hybridised to Nano-
String GeoMx® Digital Spatial Profiling (DSP) technology’soptical barcodes for ex situ digital counting and subse-
quently analysed with an nCounter® Analysis System.
2.1. Case Selection. Full ethical approval from Brain Tumour
Bank South West (REC: 11/WA/0016) was obtained for this
study. In total, 10 IDH-wild-type glioblastoma cases (5
MGMT methylated and 5 MGMT unmethylated), were se-
lected from patients diagnosed between 2012 and 2013.
MGMTmethylation status had been previously determined
by the Bristol Genetics Laboratory by the use of the pyro-
sequencing assay described by Dunn et al. with optimised
cut-offs: ≥12% methylated and ≤11% unmethylated (CpG
sites 72–83) [16]. All slides were reviewed by a certified
neuropathologist (KMK) to confirm the diagnosis. For each
specimen, one 4-μm-thick FFPE section was cut from a
single representative block and collected on adhesive glass
slides. Each of the 5 slides contained an adjacent MGMT
methylated and unmethylated GBM section. Samples were
classified as margin (≤30% in cellularity of tumour cells
compared to background reactive neuroglial tissue) and
solid tumour core (≥80% in cellularity of tumour cells
compared to background reactive neuroglial tissue), in order
to make clear distinction between the infiltrating edge and
solid centre of the tumour.
2.2. ROI Selection. +e sections (see Figure 2) were stained
with the visualization markers CD3 (red), GFAP (green),
and DNA (blue) to assist with the selection of ROIs. Six ROIs
per section were selected by aligning fluorescent images with
H&E images with ROIs predetermined by a certified neu-
ropathologist (KMK). Blood vessel and necrosis were kept to
a minimum in the selected ROI.
Each slide contained the following ROIs; denoted by
white square (Figure 2): ROIs 1–3 (tumour core-MGMT
unmethylated), ROIs 4–6 (tumour margin-MGMT unme-
thylated), ROIs 7–9 (tumour core-MGMTmethylated), and
ROIs 10–12 (tumour margin-MGMT unmethylated).
2.3. Processing. DSP enables detection of multiplexed pro-
teins from the surface of FFPE tissue and protein quanti-
tation from a defined ROI. +e cocktail of 31 antibodies
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(including controls) was applied to each FFPE unstained
section. Each antibody was conjugated to an indexing oligo
by a UV-cleavable linker. Upon highly controlled UV ex-
posure of individual ROIs by a programmable micromirror
device, the oligos were released by photocleavage and could
be removed using a microcapillary tip into a microtiter plate
[13]. Following each UV cycle, the oligos were subsequently
hybridised to NanoString GeoMx® Digital Spatial Profiling(DSP) technology’s “barcodes” and can be processed by
quantitative detection using the nCounter analysis system
providing digital counts [17] (Figure 1). +e digital counts
produced corresponded to the abundance of each targeted
protein in the ROI.
3. Data Quality Control
nCounter assays included a set of 6 positive and 6 negative
hybridization control probes, positive (POS) and negative
(NEG) A–F, respectively, to monitor hybridization effi-
ciency, prep-station purification, and imaging. POS control
targets were built into the Code Set reagent and thus re-
flected systematic variability between the assays.
POS control performance was determined by the line-
arity of counts versus protein tag set concentration. Protein
tag concentrations in the hybridization for protein tag
positive control targets ranged from 128 fM (POS_A) to
0.125 fM (POS_F) in a 4-fold titration. +e expected cor-
relation of POS control counts to protein tag target con-
centration was R2 > 0.95.
+ree data normalization systems were determined.
3.1. Positive Protein Tag Normalization (ERCC
Normalization). Data was normalised using the geometric
mean of the protein tag positive control in each sample. For
optimal results, normalization factors ranged between 0.7
and 1.7 for all assays (approximately 1.0 is optimal nor-
malization factor).
3.2. Housekeeper Normalization. S6 ribosomal protein and
histone 3 were included in the antibody panel as house-
keeper proteins.
3.3. Signal:Noise Normalization. Mouse IgG1 and Rabbit
IgG isotype controls were included in the antibody panel to
assess the signal-to-noise ratio.
Area normalization was not applicable for this study; all
ROIs were selected with the same area.
1. Stain slides with
oligo-conjugated RNA
detection probes
2. Image slide and select
Regions of interest (ROIs)
3. UV-cleave oligos of







6. Repeat for each ROI









Figure 1: Digital Spatial Profiling workflow.Morphologymarkers (GFAP, DAPI, and CD3) plus a high-plex oligo-labelled antibody cocktail
were first applied to the section. Regions of Interest (ROIs) were then selected for high-plex profiling using visible wavelength low-plex
imaging to establish the tumour “geography.” Ultraviolet was used to release the oligo tags at the selected ROIs.+e released tags were stored
in amicrotiter plate, which was then indexed and hybridized to barcodes. Up to 1million data points per ROI were digitally counted and this
data was analysed with nSolver™ Advanced Analysis Software (NanoString, 2018).
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Figure 2: (a) Photomicrographs of selected cases of glioblastoma (1–5). Each slide had a total of 12 regions of interest (ROIs) selected,
denoted by white square: ROIs 1–3 (tumour-MGMTunmethylated), ROIs 4–6 (margin-MGMTunmethylated), ROIs 7–9 (tumour-MGMT
methylated), and ROIs 10–12 (margin-MGMTunmethylated). (b) Close-up of regions of interest 1–12 selected on slide 1.+e sections were
stained with the visualization markers CD3 (red), GFAP (green), and DNA (blue). ERCC normalised data is shown below.
Table 1: Mean (SD) log 2 housekeeping normalised values by location and MGMT status.
Immunooncology targets and controls
Tumour core Tumour margin
Methylated Unmethylated Methylated U nmethylated
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
CD4 11.22 (0.65) 9.58 (1.01) 10.16 (0.84) 9.68 (0.99)
CD14 12.58 (1.61) 9.47 (1.46) 10.79 (1.07) 9.75 (1.31)
CD68 12.97 (1.00) 11.14 (0.80) 12.32 (1.14) 11.67 (1.29)
CD8A 8.30 (0.78) 6.90 (0.66) 8.06 (0.82) 7.70 (0.68)
B7-H3 14.07 (1.02) 12.35 (0.87) 12.70 (0.94) 12.52 (1.44)
PD-L1 11.50 (0.57) 10.62 (0.58) 11.47 (0.51) 11.65 (0.77)
CD19 7.77 (0.74) 6.66 (0.63) 7.47 (0.37) 7.67 (0.87)
FOXP3 7.94 (0.73) 7.02 (0.51) 7.75 (0.58) 7.88 (0.76)
CD44 15.58 (1.24) 13.30 (1.60) 13.51 (1.49) 14.80 (2.61)
STAT3 (phospho Y705) 9.41 (0.61) 8.64 (0.53) 8.52 (0.51) 9.06 (1.03)
CD45 9.19 (1.00) 7.93 (0.83) 8.25 (0.83) 8.83 (1.44)
Pan Cytokeratin 9.11 (0.67) 8.43 (0.31) 8.92 (0.30) 9.35 (0.82)
MS4A1.CD20. 7.26 (0.63) 6.47 (0.53) 7.15 (0.65) 7.50 (0.69)
CD45RO 8.29 (0.81) 7.48 (0.50) 7.88 (0.39) 8.28 (0.92)
S6 13.64 (0.30) 13.21 (0.39) 13.60 (0.32) 13.27 (0.46)
PD1 8.08 (0.73) 7.43 (0.44) 7.47 (0.72) 7.87 (0.79)
CD3 8.90 (0.61) 8.04 (1.02) 9.28 (0.70) 9.17 (1.00)
Beta-2 microglobulin 13.80 (1.12) 12.91 (0.53) 13.78 (0.69) 13.33 (1.02)
VISTA 11.94 (0.70) 11.42 (0.77) 11.80 (0.45) 12.13 (1.59)
Bcl2 10.22 (0.84) 9.70 (0.50) 9.93 (0.32) 10.51 (1.12)
GZMB 10.65 (0.47) 10.27 (0.60) 10.68 (0.68) 10.73 (0.46)
PTEN 11.29 (1.11) 10.56 (1.08) 11.13 (0.59) 11.99 (1.57)
Beta-catenin 16.19 (0.66) 16.61 (0.51) 16.53 (0.52) 17.65 (0.72)
CD56 18.40 (0.98) 17.73 (1.37) 19.26 (0.91) 19.15 (1.33)
Ki-67 11.72 (1.76) 10.81 (1.27) 10.83 (0.99) 9.96 (1.49)
STAT3 12.85 (1.44) 13.24 (0.87) 12.95 (0.83) 13.32 (0.89)
AKT 14.57 (0.68) 14.55 (0.59) 15.06 (0.56) 14.82 (1.00)
P-Akt 11.21 (0.61) 11.24 (1.46) 11.51 (0.95) 12.14 (1.16)
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4. Statistical Analyses
4.1. Preprocessing. Four ROIs (three in one sample and one
in another sample) were excluded due to low housekeeping
gene count (histone H3 <1000). Housekeeping normaliza-
tion factors were calculated by dividing the geometric mean
of histone H3 and ribosomal S6 of individual ROI by the
mean of all ROIs. +e raw count was divided by the nor-
malization factor.+e normalised data was log2 transformed
for variance stabilization.
4.2. Comparing Methylation Status. To compare the ex-
pression of genes between methylation status, the log2
normalised count was fit by the following linear mixed effect
model: Log2 normalised count∼methylation + (patient:
methylation).
Methylation is the fixed main effect that assesses the
overall difference. +e random interaction effect between
patient and methylation in the parentheses allows the effect
of methylation to vary among patients. +e model is fit with
the R package lmerTest. Log2 fold change was estimated and
the p value was inferred using Satterthwaite’s degrees of
freedom method provided in lmerTest. +e analysis was
done for tumour ROI and margin ROI separately.
5. Results
+e mean normalised count values for all 27 immune
protein targets ranged from 6.47 to 19.26 (see Table 1: mean
(SD) log 2 housekeeping normalised values by location (core
versus margin) and MGMT status). Overall, there was no
statistical difference in counts between tumour core and
tumour margin in either MGMT methylated or MGMT
unmethylated IDH-wild-type-GBM cases (Table 1). How-
ever, there was a statistically significant increase in CD4,
CD14, CD68, CD8A, B7-H3, PDL-1, CD19, FOCP3, CD44,
and STAT3 protein expression in methylated versus
unmethylated GBM tumour core (see Table 2). In the fol-
lowing, mean [SD] are reported.
5.1. Immune Cell Biomarker Counts (Table 1). We observed
comparatively low counts of CD45 pan-leukocyte marker
(MGMTunmethylated tumour core mean normalised value
(MGMTuc)� 7.93 [0.83], MGMT methylated tumour core
mean normalised value (MGMTmc)� 9.19 [1.00]), and
CD45RO isoform (MGMTuc� 7.48 [0.50] and
MGMTmc� 8.29 [0.81]) which is in keeping with low im-
mune infiltration irrespective of MGMTmethylation status
within IDH-wild-type GBM. +e mean normalised count
values of T lymphocyte marker CD3 are low
(MGMTuc� 8.04 [1.02] and MGMTmc 8.90 [0.61]) and
T-helper cell marker CD4 (MGMTuc� 9.58 [1.01] and
MGMTmc� 11.22 [0.65]), which may indicate very low
levels of T-cells and T helper cells, respectively. Both B-cell
markers CD20 (MGMTuc� 6.47 [0.53] and
MGMTmc� 7.26 [0.63]) and CD19 (MGMTuc� 6.66 [0.63]
and MGMTmc� 7.77 [0.74]) are reduced which also may
indicate a very low number of B-lymphocytes within cases.
Mean normalised values for cytotoxic T-cell marker CD8A
(MGMTuc� 6.90 [0.66] and MGMTmc� 8.30 [0.78]) may
indicate low levels of cytotoxic T cells. By comparison,
GZMB (the protease granzyme B values�MGMTuc� 10.27
[0.60] and MGMTmc� 10.65 [0.47]) shows elevated values.
GZMB is a serine protease commonly found in the granules
of cytotoxic T-cells and NK cells, and although difficult to be
certain, the mild increased values may represent a difference
in NK cells. We observed comparatively low normalised
mean values of PD-1 (MGMTuc� 7.43 [0.44] and
MGMTmc� 8.08 [0.73]) in keeping with overall compara-
tively low T-cell-associated proteins in our cohort.
5.2. Immune Checkpoint and Cancer Biomarker Counts
(Table 2). Table 2 shows p-values for MGMTcomparison in
tumour core (column 2) and margin (column 3) and for
comparing core against margin in methylated (column 4)
and in unmethylated (column 5). Overall there was a sta-
tistically significant difference between methylated and
unmethylated tumour cores, but not tumour margins.
GeoMx DSP shows 10/27 immunooncology target proteins
were significantly increased in methylated versus unme-
thylated IDH-wild-type glioblastoma tumour core but not
margin (false discovery rate (FDR)<0.1, by Benjami-
ni–Hochberg procedure). In particular, there was a
statistically significant increase in CD4, CD14, CD68, CD8A,
B7-H3, PDL-1, CD19, FOXP3, CD44, and STAT3 protein
expression in methylated versus unmethylated GBM tumour
core (see Table 2). +ere was no statistically significant
difference in PD-1, VISTA, CD45, CD45RO, CD3, CD20,
GZMB, STAT3 (phospho Y705), beta-2 microglobulin,
CD56, beta-catenin, AKT, P-AKT, PTEN, Bcl2, Pan Cyto-
keratin, and Ki-67 protein expression.
In particular, in our cohort, checkpoint biomarker PD-
L1 is statistically increased in MGMT methylated tumour
cores compared with unmethylated tumour cores of GBMs
(p � 0.025) (see Table 2). +e checkpoint molecule B7-H3
(CD276) is statistically increased in MGMT methylated
tumour cores compared with unmethylated tumour cores of
GBMs (p � 0.023); MGMTmethylated tumour core counts:
14.07 [1.02] compared to MGMT unmethylated GBM (tu-
mour core: 12.35 [0.87]). V-domain immunoglobulin sup-
pressor of T-cell activation VISTA is homologous to PD-L1
and a suppressor of T-cell activation, synergising with PD-1.
By contrast, VISTA is not statistically increased in MGMT
methylated tumour cores compared with unmethylated
tumour cores of GBMs (p � 0.153); MGMT methylated tu-
mour core (11.94 [0.70]) and MGMTunmethylated tumour
core (11.42 [0.77]) although mean normalised counts are
increased.
6. Discussion
In this paper, we used NanoString GeoMx® Digital SpatialProfiling (DSP) technology to analyse multiple immu-
nooncology targets in methylated against unmethylated
IDH-wild-type GBM tumours. NanoString GeoMx® DigitalSpatial Profiling (DSP) technology has the theoretical ability
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to analyse a potential of 800 protein targets, therefore
allowing in-depth analysis of panels of tissue-based prog-
nostic and predictive biomarkers, in-depth monitoring of
response to therapies, and more rapid identification of
targets of disease. +e small sample of this technology
feasibility study requires further validation of results in
larger cohorts.
6.1. Immune Infiltration. +e mean log 2 housekeeping
normalised values by location and MGMT status for all 27
immune protein targets ranged from 6.47 to 19.26 in our
study (Table 1). NanoString GeoMx® Digital Spatial Pro-filing (DSP) technology has been tested in several studies
reporting its robustness, sensitivity, and reproducibility
[18–20]. However, one potential disadvantage we identified
using the technique was the lack of ability to draw direct
comparisons between count values and immune cell
numbers within samples because it is not possible to visu-
alise cells and also there was a complex normalization
process and no standardised normalised tables were avail-
able for comparison. For example, the mean normalised
values of CD3 (MGMTuc� 8.04 [1.02] and MGMTmc� 8.90
[0.61]) and CD4 (MGMTuc� 9.58 [1.01] and
MGMTmc� 11.22 [0.65]) may indicate very low levels of
T-cells and T-helper cells, respectively, within the tumours
(see Table 2). In turn, both CD20 (MGMTuc� 6.47 [0.53]
and MGMTmc� 7.26 [0.63]) and CD19 (MGMTuc� 6.66
[0.63] and MGMTmc� 7.77 [0.74]) may indicate a low
number of B lymphocytes. Mean normalised values for
CD8A (MGMTuc� 6.90 [0.66] and MGMTmc� 8.30 [0.78])
may indicate low levels of cytotoxic T cells in the specimens
studied; however, by comparison, GZMB (the protease
granzyme B values�MGMTuc 10.27 [0.60], MGMTmc
10.65 [0.47]) showed comparatively elevated values. GZMB
is a serine protease commonly found in the granules of
cytotoxic T-cells and NK cells, and although difficult to be
certain, it raises the possibility of increased NK cells within
these specimens.+ese findings however are in keeping with
previous work in malignant gliomas suggesting that B-cells
and the subtypes of T-cells are found in these tumours to
varying degrees, with particularly low numbers of B-cells
and CD4 helper T-cells [21]. Here, we observed compara-
tively low values for CD45RO (MGMTuc� 7.48 [0.50] and
MGMTmc� 8.29 [0.81]) and CD45 (MGMTuc� 7.93 [0.83]
and MGMTmc� 9.19 [1.00]), which is in keeping with low
immune infiltration irrespective of MGMT methylation
status. Previous work has also suggested sparse-to-moderate
Table 2: p values for MGMT comparison in tumour core (column 2) and margin (column 3) and for comparing core against margin in
methylated (column 4) and in unmethylated (column 5).
Immunooncology targets and
controls









CD4 0.005 0.452 0.050 0.452
CD14 0.006 0.246 0.117 0.246
CD68 0.007 0.416 0.316 0.416
CD8A 0.011 0.383 0.617 0.383
B7-H3 0.023 0.793 0.087 0.793
PD-L1 0.025 0.639 0.875 0.639
CD19 0.028 0.614 0.406 0.614
FOXP3 0.030 0.722 0.577 0.722
CD44 0.032 0.451 0.068 0.451
STAT3 (phospho Y705) 0.034 0.396 ∗0.048 0.396
CD45 ∗0.041 0.358 0.125 0.358
Pan Cytokeratin ∗0.048 0.370 0.617 0.370
MS4A1/CD20 0.053 0.347 0.738 0.347
CD45RO 0.093 0.438 0.379 0.438
S6 0.100 0.218 0.928 0.218
PD1 0.121 0.390 0.205 0.390
CD3 0.144 0.830 0.259 0.830
Beta-2 microglobulin 0.147 0.423 0.981 0.423
VISTA 0.153 0.663 0.624 0.663
Bcl2 0.230 0.376 0.499 0.376
GZMB 0.274 0.317 0.155 0.317
PTEN 0.292 0.239 0.790 0.239
Beta-catenin 0.296 ∗0.025 0.473 ∗0.025
CD56 0.357 0.860 0.105 0.860
Ki-67 0.378 0.279 0.358 0.279
STAT3 0.634 0.619 0.841 0.619
AKT 0.946 0.644 0.207 0.644
P-Akt 0.978 0.353 0.505 0.353
∗Bold ∗Values statistically significant after Benjamini–Hochberg adjustment for False Discovery Rate at 0.1. ∗Values statistically significant if unadjusted but
not statistically significant after Benjamini–Hochberg adjustment for False Discovery Rate at 0.1.
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density of TILs in 85 of 117 (72.6%) IDH-wild-type glio-
blastoma specimens (CD3+ 78/117, 66.7%; CD8+ 52/117,
44.4%; CD20 + 27/117, 23.1%) [12]. Furthermore, another
study has shown TILs were enriched in glioblastomas of the
mesenchymal class [22]. Yang et al. have reported that an
increased immune infiltrate of CD8+ cytotoxic T-cells
predicts improved long-term survival in patients with
glioblastoma [23]; however, this has not been replicated in
many other studies. In our study, CD8 was not found to be
increased in methylated compared to unmethylated tumour
cores; however, this study did not directly compare CD8
expression with patient survival.
A direct lineage of CD4+ T-cells and T-regulatory cells is
CD3+ CD4+ T-cells. T-regulatory cells suppress the re-
sponse of self-reactive T-cells and downregulate antitumour
immunity. Tregs express the unique transcriptional re-
pressor protein FOXP3 [24]. We observed a statistically
significant difference in FOXP3 (p � 0.03) between MGMT
methylated and unmethylated tumour core, although overall
counts are low (MGMTuc� 7.02 [0.51] andMGMTmc� 7.94
[0.73]). In a recent study of 186 IDH-wild-type glioblastoma
patients, consecutively treated with radiochemotherapy, the
presence of FoxP3 + cells was associated with a better overall
survival (p � 0.04; HR: 0.62 [95% CI: 0.4–0.98]) [25], al-
though other studies have shown that FoxP3+ infiltrate is
associated with tumour recurrence [26]. Additionally, in a
study by Fecci et al., it has been shown that absolute counts
of both CD4+ T-cells and CD4+ CD25+ FOXP3+
CD45RO+T-cells (i.e., Tregs) are reduced in patients with
malignant glioma, yet there is an increased fraction of the
CD4+ compartment [27]. In another cohort of 135 gliomas
including 52 glioblastomas regardless of pathological type,
the median survival was 43months [(95% confidence in-
terval [CI], 26.9—not available months) in patients whose
tumours stained negatively for FoxP3. In contrast, the
median survival duration was 19.2 months (95% CI,
13.8–34.0months) in patients whose tumours contained
FoxP3+ Tregs (p< 0.001). It must be noted that this finding
did not account for the confounding influence of tumour
grade on survival. In this cohort, patients with higher grade
gliomas, who have shorter overall survival, were more likely
to have greater Tregs infiltration than patients with lower-
grade gliomas. However, when the group performed uni-
variate Cox proportional hazards analysis within glioma
pathological subtypes, the percentage of cells that stained
positive for FoxP3 did not seem to correlate with survival
duration [28]. +e degree of variability in the available
literature on the impact of T-regulatory cells onOS of glioma
patients, alongside the increased FoxP3 levels in methylated
compared to unmethylated tumour core, signifies the need
for further investigation.
6.2. Immune Checkpoints. PD-L1 on glioblastoma cells in-
teracts with PD-1 normally expressed on the surface of
T-cells and this interaction may suppress T-cell activation.
In our cohort, PD-L1 expression is statistically increased in
MGMT methylated tumour cores compared with unme-
thylated tumour cores of GBMs (p � 0.025). CheckMate 143
also showed evidence of increased PD-L1 expression in a
cohort 27/40 (68%) glioblastoma raising the possibility of
PD-L1 inhibitor (nivolumab) use in clinical practice [10].
However, preliminary results, published in a World Fed-
eration of Neuro-Oncology Society (WFNOS) Meeting 2017
abstract, demonstrated a failure of PD-I inhibitor nivolumab
to prolong overall survival of patients with recurrent glio-
blastoma, and this arm of the trial was prematurely closed
[11]. One explanation for this lack of efficacy of nivolumab
could be the lack of immune T-cells within GBM in line with
observed comparatively low normalised mean count values
of PD-1 (MGMTuc� 7.43 [0.44] and MGMTmc� 8.08
[0.73]) and in keeping with overall comparatively low T-cell
associated proteins in our cohort, compared with PD-L1
(MGMTuc� 11.50 ([0.57] and MGMTmc� 10.62 [0.58]).
In addition, we observed higher overall mean normalised
values of the checkpoint molecule B7-H3 (CD276) irre-
spective of methylation status; MGMTmethylated (tumour
core: 14.07 [1.02], MGMTmethylated tumour margin: 12.70
[0.94]) compared to MGMT unmethylated GBM (tumour
core: 12.35 [0.87], tumour margin: 12.52 [1.44]). We also
noted a statistical increase of B7-H3 in MGMTmethylated
tumour core B7-H3 (CD276) against MGMT unmethylated
tumour core (p � 0.023). A similar expression pattern has
recently been reported by a study (n� 994) by Wang et al.
who demonstrated B7-H3 upregulation in high-grade gli-
oma and hence lower overall survival [29]. B7-H3 (CD276),
which belongs to the B7 superfamily, has been shown to
costimulate the proliferation of CD4+ and CD8+ T-cells,
enhances the induction of cytotoxic T-cells, and stimulates
interferon gamma production [30]. In comparison to PD-1
and CTLA-4 checkpoints, the mechanism of B7-H3
(CD276) in suppressing tumour development still remains
unclear [31]. Considering the conclusions drawn by Wang
et al. and the emerging evidence from this small-sample
study, B7-H3 may be a potential therapeutic target that
requires further investigation.
V-domain immunoglobulin suppressor of T-cell acti-
vation (VISTA), which is homologous to PD-L1, is a sup-
pressor of T-cell activation, synergising with PD-1 [32, 33].
In addition, VISTA has also been shown to activate Tregs
[34]. In our study, VISTA mean normalised counts were on
the higher end of the normalised values’ range in both
MGMTmethylated and unmethylated IDH-wild-type GBM;
however, there was no significant difference between groups:
MGMT methylated tumour core 11.94 [0.70], MGMT
unmethylated tumour core 11.42 [0.77].
Although in our small study there was a statistically
significant increase in CD4, CD14, CD68, CD8A, B7-H3,
PDL-1, CD19, FOXP3, CD44, and STAT3 protein expres-
sion in methylated versus unmethylated GBM tumour core
(see Table 2), we need to be cautions with these results due to
the small sample size that requires further exploration and
validation in larger cohorts using DSP.
7. Limitations
+e small size of our cohort limits interpretation. In this
study, the four main sources of variation in using DSP are
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nCounter quantification, ROI background, ROI size, and
ROI cellularity [20]. Section-to-section proximity and
alignment may lead to small fluctuations in raw, normalised,
and relative nCounter data. In addition, section-to section
variability may lead to decreased reproducibility of counts.
Antibody cocktail lot variation may affect raw and positive
protein tag normalization (ERCC normalization) nCounter
counts. According to protocol, antibody cocktails are pre-
pared fresh (i.e., weekly) which may lead to additional
variation. In addition, pipetting variability and lot age can
lead to differences in overall nCounter counts that can be
corrected by housekeeping normalization.
Another disadvantage of DSP technology is that it only
permits targeted discovery, and a selection of targets is
required to be included in the cocktail of antibodies, rather
than “pure discovery” [35]. Other than quantifying immune
protein targets, this multiplex platform does not inform the
mechanistic nature, properties, and function of the complex
cellular and molecular pathways that take place in the ROI as
these occur in space and time. NanoString GeoMx® DigitalSpatial Profiling (DSP) technology produces high-dimen-
sional multiplex data, which can complicate the normali-
zation process and calls for caution and consistency when
analysing the results, possibly in collaboration with com-
putational scientists [20].
8. Conclusion
In our experience, careful consideration of the experimental
design and normalization process, with simultaneous in-
depth understanding of DSP normalization may optimise
results. In this small study, there was a statistical increase in
CD4, CD14, CD68, CD8A, B7-H3, PDL-1, CD19, FOXP3,
CD44, and STAT3 protein expression in methylated versus
unmethylated GBM tumour core; however, this requires
larger cohort validation. Advanced multiplex immu-
nooncological predictive biomarker analysis may underpin a
future personalised medicine approach in the use of targeted
immunotherapeutic agents in glioblastoma.
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